Leadership team
Pheon has a very strong leadership team of specialists, bringing together the best of clinical and managerial expertise with a proven track record in targeted oncology therapies and ADCs.
Paul Jackson
Vice President of R&D and Co-founder
Paul Jackson has over 10 years’ experience in the Antibody-Drug Conjugate field, initially in the design/discovery of small molecule payloads and subsequently pre-clinical development of ADCs. Paul is inventor on 28 patent applications and has published 15 papers in the field.
After completing undergraduate and post-graduate degrees in pharmaceutical sciences and bioinformatics at LJMU and University of Liverpool, Dr Jackson earned his PhD in the laboratory of Prof. David Thurston at King’s College London, where he developed in silico molecular dynamics-based methods for the design of sequence-selective DNA-interactive ADC payloads. Dr Jackson then carried out postdoctoral research at King’s College, utilizing methods developed in his doctoral studies to design new classes of ADC payloads and co-founded Pheon Therapeutics, (previously Femtogenix) to commercialize the newly developed agents. Paul led Pheon Therapeutics’ operations from its foundation in 2015, leading R&D on a day-to-day basis and business development activities. Paul has experience of negotiating and closing licensing agreements, alliance management and corporate development.
